New Medicare Benefits Schedule (MBS) item for faecal calprotectin testing

From 1 November 2025 patients diagnosed with IBD who are symptomatic will be able to access a Medicare benefit for a faecal test to support the management of their condition.

The new item allows practitioners to request a Medicare funded pathology service for symptomatic diagnosed IBD patients to inform the management of their disease.

Thank you to the CCA community for providing important feedback into this approval.

You can read more here.

Crohn’s & Colitis Australia (CCA)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.